Item 7.01. Regulation FD Disclosure.

Story continues below

The information in this Current Report (including Exhibits 99.1 and 99.2) are being furnished and shall not be deemed “filed” for the purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Securities Exchange Act of 1934”), or otherwise subject to the liabilities of that Section. The information in this Current Report (including Exhibits 99.1 and 99.2) shall not be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

On August2, 2017, the Company issued a press release announcing positive top-line results from a Phase 2b study of velusetrag (TD-5108) in patients with gastroparesis. A copy of the press release is filed as Exhibit99.1 hereto and incorporated by reference into this Current Report on Form8-K. Theravance Biopharma management will discuss these results on a conference call on August2, 2017 at 5:00 p.m.Eastern Daylight Time. A copy of the press release and the slide presentation to be presented during the conference call are furnished as Exhibits 99.1 and 99.2 to this report and are incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.


99.1 Press Release Dated August2, 2017

99.2 Velusetrag (TD-5108) Top-line Results from Phase 2b Study in Gastroparesis Slide Presentation Dated August 2, 2017

Theravance Biopharma, Inc. Exhibit
EX-99.1 2 a17-18737_1ex99d1.htm EX-99.1 Exhibit 99.1     Theravance Biopharma Announces Positive Top-Line Results from Phase 2b Study of Velusetrag (TD-5108) in Patients with Gastroparesis   Improvements in Symptoms and Normalized Gastric Emptying Demonstrated in both Diabetic and Idiopathic Gastroparesis Patients   DUBLIN,…
To view the full exhibit click here


Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.

An ad to help with our costs